All In Biotech

Investigational drug · Phase 2

RRG001

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neovascular Age-related Macular Degeneration.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "RRG001"

First trial start

2023

Dec 12, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RRG001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neovascular Age-related Macular Degeneration

Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "RRG001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Neovascular Age-related Macular Degeneration

  • OTX-TKIaxitinib implantPhase 33 trials

    Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)

  • IBI302Phase 32 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema

  • Surabgene LomparvovecABBV-RGX-314Phase 32 trials

    AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration

  • ABP 938Phase 31 trial

    Amgen · Neovascular Age-related Macular Degeneration, nAMD

  • ASKG712AM712, VIS-101Phase 21 trial

    Visara, Inc. · Neovascular Age-related Macular Degeneration

  • SAR402663Phase 21 trial

    Sanofi · Neovascular Age-related Macular Degeneration

  • SYL1801Phase 21 trial

    Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.